Sutro Biopharma receives Nasdaq minimum bid price deficiency notice; has until Dec 17, 2025 to cure

SUTRO BIOPHARMA, INC.

Nasdaq notified Sutro on June 20, 2025 of non-compliance with $1.00 minimum bid price rule.
Company has 180 calendar days, until December 17, 2025, to regain compliance by closing at $1.00 for 10 consecutive days.
If not cured, Sutro may transfer to Nasdaq Capital Market for a second 180-day period or face delisting.
Sutro plans to monitor bid price and may implement a reverse stock split if needed.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.